Latest Anocca News & Updates

See the latest news and media coverage for Anocca. We track all announcements, press releases, and industry mentions in real time, all in one place.

Anocca

Precision T-cell immunotherapy company

anocca.com

Headquarters: Södertälje, Sweden
Founded year: 2014
Company type: Private company
Number of employees: 100–200

Last updated Today

Latest news about Anocca

In short: Anocca advanced its clinical pipeline by dosing the first patients with its KRAS-targeted precision TCR-T cell therapy for cancer.

Company announcements

June 11 Anocca

Anocca dosed first patients with KRAS-targeted TCR-T therapy

ANOC-001 is a non-viral gene-edited therapy for pancreatic ductal adenocarcinoma, part of the VIDAR-1 clinical programme.

May 12 Anocca

Anocca publishes minutes from the 2026 annual general meeting

The minutes contain decisions from the annual general meeting and can be downloaded as a PDF.

April 14 Anocca

Anocca calls for annual general meeting on May 12, 2026

The meeting is held in Stockholm with proposals for emissions and election of board.

April 14 Anocca

Anocca publishes annual report for 2025

The report is available as a PDF and summarizes the company's financial results.

Media coverage

June 11 City A.M.

Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

Anocca AB (‘Anocca’ or the ‘Company’), a clinical-stage biotechnology company developing advanced T-cell immunotherapies, ...

19 August 2025 Yahoo Finance

Anocca secures $46m to support pancreatic cancer therapy trials

Swedish biotechnology company Anocca has secured approximately Skr440m ($46m) to primarily support...

30 July 2025 Nasdaq

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

MaxCyte's Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca's TCR-T cell therapies ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) ...

17 March 2025 Ny Teknik

Anocca has received regulatory approval to start a clinical study in patients with advanced pancreatic cancer

• First in human-study VIDAR-1 in advanced pancreatic cancer will be conducted at eight leading university hospitals in Sweden, Denmark, Germany and the Netherlands • Anocca is a Swedish...

Never miss news about Anocca

Track Anocca and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Anocca competitors & trending companies

Browse news for competitors to Anocca and other trending companies.